|
|
Article: CSL Biotherapies Reaches Agreement with Merck & Co. on Rights to Market and Distribute Afluria[R] in the U.S.
- Article from:
- Vaccine Weekly
- Article date:
- October 14, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CSL Biotherapies and its parent company, CSL Limited (ASX:CSL), one of the world's leading manufacturers of influenza vaccine, have reached an agreement with Merck & Co., Inc. on rights to market and distribute Afluria[R] in the United States under an exclusive, six-year agreement effective September 3, 2009. Afluria, a CSL product, is a non-adjuvanted trivalent seasonal influenza vaccine sold in two different formulations: thimerosal-free, pre-filled syringes, and in multi-dose vials (see also CSL Biotherapies).
Merck will have the exclusive right to sell and distribute Afluria in the United States beginning with the 2010/11 seasonal influenza season. The ...